JP2018508218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508218A5
JP2018508218A5 JP2017546178A JP2017546178A JP2018508218A5 JP 2018508218 A5 JP2018508218 A5 JP 2018508218A5 JP 2017546178 A JP2017546178 A JP 2017546178A JP 2017546178 A JP2017546178 A JP 2017546178A JP 2018508218 A5 JP2018508218 A5 JP 2018508218A5
Authority
JP
Japan
Prior art keywords
binding protein
amino acid
isolated binding
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546178A
Other languages
English (en)
Japanese (ja)
Other versions
JP6845802B2 (ja
JP2018508218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020779 external-priority patent/WO2016141244A1/en
Publication of JP2018508218A publication Critical patent/JP2018508218A/ja
Publication of JP2018508218A5 publication Critical patent/JP2018508218A5/ja
Application granted granted Critical
Publication of JP6845802B2 publication Critical patent/JP6845802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546178A 2015-03-04 2016-03-03 トランスフォーミング増殖因子β1に高親和性、アビディティおよび特異性で結合するscFv−Fc二量体 Active JP6845802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128133P 2015-03-04 2015-03-04
US62/128,133 2015-03-04
PCT/US2016/020779 WO2016141244A1 (en) 2015-03-04 2016-03-03 scFv-Fc DIMERS THAT BIND TRASFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

Publications (3)

Publication Number Publication Date
JP2018508218A JP2018508218A (ja) 2018-03-29
JP2018508218A5 true JP2018508218A5 (cg-RX-API-DMAC7.html) 2019-03-28
JP6845802B2 JP6845802B2 (ja) 2021-03-24

Family

ID=55538640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546178A Active JP6845802B2 (ja) 2015-03-04 2016-03-03 トランスフォーミング増殖因子β1に高親和性、アビディティおよび特異性で結合するscFv−Fc二量体

Country Status (15)

Country Link
US (4) US10508146B2 (cg-RX-API-DMAC7.html)
EP (2) EP3265484B1 (cg-RX-API-DMAC7.html)
JP (1) JP6845802B2 (cg-RX-API-DMAC7.html)
KR (3) KR102754133B1 (cg-RX-API-DMAC7.html)
CN (1) CN107889491B (cg-RX-API-DMAC7.html)
AR (1) AR103839A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016226097B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018767A2 (cg-RX-API-DMAC7.html)
ES (1) ES3014555T3 (cg-RX-API-DMAC7.html)
IL (1) IL254238B (cg-RX-API-DMAC7.html)
MX (2) MX2017011251A (cg-RX-API-DMAC7.html)
RU (1) RU2733286C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201912449UA (cg-RX-API-DMAC7.html)
TW (1) TWI726870B (cg-RX-API-DMAC7.html)
WO (1) WO2016141244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN112500491B (zh) * 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
CN116179493A (zh) * 2021-09-29 2023-05-30 成都美杰赛尔生物科技有限公司 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1486560A3 (en) 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのTGF−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
JP2008513542A (ja) 2004-09-22 2008-05-01 ジェンザイム・コーポレイション 免疫抑制剤の腎毒性を制限するためのTGF−βアンタゴニストの使用
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
PT1874818E (pt) 2005-04-22 2011-05-05 Lilly Co Eli Anticorpos espec?ficos contra tgf beta 1
BRPI0620240A2 (pt) 2005-12-23 2011-11-08 Lilly Co Eli anticorpo monoclonal, uso do mesmo e composição farmaceutica
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
KR20090013763A (ko) 2006-03-23 2009-02-05 기린 파마 가부시끼가이샤 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
CN102264390A (zh) * 2008-07-02 2011-11-30 新兴产品开发西雅图有限公司 Il6免疫治疗
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
EP2655624B1 (en) * 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
AU2014249051B2 (en) * 2013-03-11 2018-02-15 Genzyme Corporation Engineered anti-TGF-beta antibodies and antigen-binding fragments
CN105229028B (zh) 2013-03-20 2019-11-08 建新公司 用于治疗成骨不全的方法
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體

Similar Documents

Publication Publication Date Title
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2018508218A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2020528768A5 (cg-RX-API-DMAC7.html)
JP2010533498A5 (cg-RX-API-DMAC7.html)
JP2018512124A5 (cg-RX-API-DMAC7.html)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2017529838A5 (cg-RX-API-DMAC7.html)
JP2017029157A5 (cg-RX-API-DMAC7.html)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2017534259A5 (cg-RX-API-DMAC7.html)
JP2011526785A5 (cg-RX-API-DMAC7.html)
JP2009525764A5 (cg-RX-API-DMAC7.html)
JP2012509881A5 (cg-RX-API-DMAC7.html)
JP2015503909A5 (cg-RX-API-DMAC7.html)
AU2017252343B2 (en) Humanized anti CLEVER-1 antibodies and their use
RU2017134042A (ru) ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ
JP2016502515A5 (cg-RX-API-DMAC7.html)
JP2017532005A5 (cg-RX-API-DMAC7.html)
JP2019521647A5 (cg-RX-API-DMAC7.html)
JP7679399B2 (ja) 抗flt3抗体及び組成物
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2012524524A5 (cg-RX-API-DMAC7.html)